Devender Dhanda

533 total citations
33 papers, 281 citations indexed

About

Devender Dhanda is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Devender Dhanda has authored 33 papers receiving a total of 281 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 15 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Devender Dhanda's work include Multiple Myeloma Research and Treatments (17 papers), CAR-T cell therapy research (10 papers) and Protein Degradation and Inhibitors (6 papers). Devender Dhanda is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), CAR-T cell therapy research (10 papers) and Protein Degradation and Inhibitors (6 papers). Devender Dhanda collaborates with scholars based in United States, Spain and United Kingdom. Devender Dhanda's co-authors include Uday B. Kompella, N. Cheruvu, Sidney S. Mirvish, Puneet Tyagi, Nina Shah, Julia Braverman, Nikhil C. Munshi, Timothy Campbell, Michel Delforge and Jesús F. San Miguel and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Devender Dhanda

27 papers receiving 274 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Devender Dhanda United States	10	107	105	71	70	63	33	281
Shahriar Absar United States	11	229 2.1×	13 0.1×	88 1.2×	82 1.2×	61 1.0×	13	452
Jonas Wilbs Switzerland	7	30 0.3×	53 0.5×	41 0.6×	163 2.3×	17 0.3×	12	340
Jolanda M. van den Hoven Netherlands	6	36 0.3×	20 0.2×	20 0.3×	108 1.5×	71 1.1×	7	351
Samina Afzal Canada	10	29 0.3×	48 0.5×	20 0.3×	90 1.3×	9 0.1×	15	283
Haoran Ji China	5	29 0.3×	40 0.4×	15 0.2×	47 0.7×	38 0.6×	6	331
Eucharist Kun United States	7	23 0.2×	61 0.6×	5 0.1×	107 1.5×	24 0.4×	12	230
Yihan Sun United States	9	30 0.3×	60 0.6×	20 0.3×	85 1.2×	6 0.1×	17	308
Haihan Song China	11	28 0.3×	83 0.8×	9 0.1×	117 1.7×	3 0.0×	23	316

Countries citing papers authored by Devender Dhanda

Since Specialization

Citations

This map shows the geographic impact of Devender Dhanda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devender Dhanda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devender Dhanda more than expected).

Fields of papers citing papers by Devender Dhanda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devender Dhanda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devender Dhanda. The network helps show where Devender Dhanda may publish in the future.

Co-authorship network of co-authors of Devender Dhanda

This figure shows the co-authorship network connecting the top 25 collaborators of Devender Dhanda. A scholar is included among the top collaborators of Devender Dhanda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devender Dhanda. Devender Dhanda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Braverman, Julia, Gill Worthy, James W. Shaw, et al.. (2024). A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology. Value in Health. 27(4). 458–468. 4 indexed citations

Leleu, Xavier, Alfred Chung, Noopur Raje, et al.. (2024). P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B. Clinical Lymphoma Myeloma & Leukemia. 24. S67–S67. 1 indexed citations

Jansen, Jeroen P., et al.. (2024). Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma. Value in Health. 27(8). 1012–1020.

Delforge, Michel, Krina K. Patel, Devender Dhanda, et al.. (2024). Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. The Lancet Haematology. 11(3). e216–e227. 17 indexed citations

Cope, Shannon, et al.. (2023). MSR31 Applying Multi-Level Network Meta-Regression (ML-NMR) to a Case Study in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM). Value in Health. 26(6). S283–S283.

Karampampa, Korinna, et al.. (2023). Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France. Journal of Medical Economics. 26(1). 243–253. 7 indexed citations

Ramasamy, Karthik, Hartmut Goldschmidt, Philippe Moreau, et al.. (2023). P945: REAL-WORLD CLINICAL OUTCOMES AMONG TRIPLE-CLASS EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS IN US AND EUROPE: A PREAMBLE REGISTRY STUDY. HemaSphere. 7(S3). e642555a–e642555a.

Karampampa, Korinna, et al.. (2023). CO53 A Review of Treatment Effect Modifiers and/or Prognostic Factors Included in Unanchored Indirect Treatment Comparisons (ITCs) Involving Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM). Value in Health. 26(12). S23–S24.

Delforge, Michel, Krina K. Patel, Devender Dhanda, et al.. (2023). Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial. Blood. 142(Supplement 1). 96–96. 2 indexed citations

10.

Delforge, Michel, Paula Rodríguez‐Otero, Nina Shah, et al.. (2023). Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leukemia Research. 129. 107074–107074. 11 indexed citations

11.

Tanaka, Eiichi, Eisuke Inoue, Ayako Shoji, et al.. (2022). Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLoS ONE. 17(11). e0277566–e0277566. 3 indexed citations

12.

Andrade, Jason G., Richard Godin, Tereza Lanitis, et al.. (2022). Cost-effectiveness of atrial fibrillation screening in Canadian community practice. Heart Rhythm O2. 4(2). 103–110. 2 indexed citations

13.

Shah, Nina, Michel Delforge, Jesús F. San Miguel, et al.. (2022). Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. Leukemia Research. 120. 106921–106921. 9 indexed citations

14.

Shah, Nina, Dieter Ayers, Shannon Cope, et al.. (2022). Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. Journal of Comparative Effectiveness Research. 11(10). 737–749. 10 indexed citations

15.

Braverman, Julia, et al.. (2021). PCN221 Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy: Qualitative Analyses of Early Post-Treatment Interviews With Relapsed and Refractory Multiple Myeloma (RRMM) Patients in the KarMMa Clinical Trial. Value in Health. 24. S61–S61. 1 indexed citations

16.

Fusco, Manuela Di, Carlos Polanco, Amiee Kang, et al.. (2021). Cost-effectiveness analysis of apixaban versus vitamin K antagonists for antithrombotic therapy in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention in Spain. PLoS ONE. 16(11). e0259251–e0259251. 3 indexed citations

17.

Rodríguez‐Otero, Paula, Dieter Ayers, Devender Dhanda, et al.. (2021). Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up. Blood. 138(Supplement 1). 1978–1978. 1 indexed citations

18.

Dhanda, Devender, Puneet Tyagi, Sidney S. Mirvish, & Uday B. Kompella. (2013). Supercritical fluid technology based large porous celecoxib–PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. Journal of Controlled Release. 168(3). 239–250. 43 indexed citations

19.

Dhanda, Devender & Uday B. Kompella. (2005). Metered Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs) for Pulmonary Drug Delivery: CMC Issues. Clinical Research and Regulatory Affairs. 22(1). 31–55. 1 indexed citations

20.

Dhanda, Devender, et al.. (2004). Pulmonary Delivery of Deslorelin: Large-Porous PLGA Particles and HPβCD Complexes. Pharmaceutical Research. 21(7). 1119–1126. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shahriar Absar Breakdown of academic impact, for papers by Jonas Wilbs Breakdown of academic impact, for papers by Jolanda M. van den Hoven Breakdown of academic impact, for papers by Samina Afzal Breakdown of academic impact, for papers by Haoran Ji Breakdown of academic impact, for papers by Eucharist Kun Breakdown of academic impact, for papers by Yihan Sun Breakdown of academic impact, for papers by Haihan Song